MAIA News & Events

MAIA Biotechnology announced that net proceeds from its $33M public offering of common stock in March are expected to fully fund the company's ongoing pivotal Phase 3 clinical trial of its lead investigational therapy, ateganosine, as a treatment for non-small cell lung cancer. Ateganosine is a dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. The FDA has granted Fast Track designation for the drug in third line NSCLC treatment.

MAIA Biotechnology announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by the company. MAIA intends to use the net proceeds from the offering to conduct clinical trials and for working capital and general corporate purposes. Konik Capital Partners, a division of T.R. Winston & Company, is acting as the sole book-running manager for the offering.

MAIA Biotechnology published a 2026 Letter to Shareholders by Founder and CEO Vlad Vitoc, M.D. featuring the Company's strong momentum in clinical trials of its lead molecule, ateganosine, as a treatment for non-small cell lung cancer. As stated in the Letter, Dr. Vitoc wrote, "Our development strategy intentionally targets the third-line NSCLC population, where the unmet need is urgent. No established standard of care exists in 3L treatment, with most oncologists currently treating 3L patients with chemotherapy, leading to particularly poor clinical outcomes. In clinical studies, ateganosine sequenced with an immune checkpoint inhibitor has demonstrated outcomes that exceed those historically achieved with either CPI-based therapy or chemotherapy alone. These findings position ateganosine not as a competitor to CPIs, but as the foundation of a new treatment category designed specifically for advanced NSCLC following CPI and chemotherapy failure. By focusing on a third-line population with no defined standard of care, we are addressing an underserved group of approximately 50,000 patients annually in the United States and creating a differentiated, incremental revenue opportunity outside of the CPI market."